Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP

Francesco Onida*, Giulia Sbianchi, Aleksandar Radujkovic, Katja Sockel, Nicolaus Kröger, Jorge Sierra, Gerard Socié, Jan Cornelissen, Xavier Poiré, Luděk Raida, Jean Henri Bourhis, Jürgen Finke, Jakob Passweg, Urpu Salmenniemi, Harry C. Schouten, Yves Beguin, Sonja Martin, Eric Deconinck, Arnold Ganser, Samo ZverBruno Lioure, Radia Rohini, Linda Koster, Patrick Hayden, Simona Iacobelli, Marie Robin, Ibrahim Yakoub-Agha

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)–CMML: WBC 10–20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.

Original languageEnglish
Pages (from-to)896-902
Number of pages7
JournalBone Marrow Transplantation
Volume57
Issue number6
Early online date29 Mar 2022
DOIs
Publication statusPublished - Jun 2022

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.

Fingerprint

Dive into the research topics of 'Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP'. Together they form a unique fingerprint.

Cite this